1. A PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R) SYSTEMIC ANAPLASTIC LARGE‐CELL LYMPHOMA (SALCL) OR R/R HODGKIN LYMPHOMA (HL). (June 2017) Authors: Locatelli, F.; Mauz‐Koerholz, C.; Neville, K.; Llort, A.; Beishuizen, A.; Daw, S.; Pillon, M.; Aladjidi, N.; Klingebiel, T.; Landman‐Parker, J.; Medina‐Sanson, A.; August, K.; Huebner, D.; Sachs, J.; Hoffman, K.; Kinley, J.; Song, S.; Song, G.; Zhang, S.; Gore, L. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 248 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. RESPONSE‐ADAPTED TREATMENT WITH NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN YOUNG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 744 SUBGROUP ANALYSES. (12th June 2019) Authors: Kelly, K.M.; Daw, S.; Mauz‐Körholz, C.; Mascarin, M.; Michel, G.; Cooper, S.; Beishuizen, A.; Leger, K.J.; Garaventa, A.; Buffardi, S.; Brugières, L.; Harker‐Murray, P.; Cole, P.D.; Drachtman, R.A.; Manley, T.; Francis, S.; Sacchi, M.; Leblanc, T. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S204: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONTLINE CHEMOTHERAPY: THE PHASE 2, OPEN-LABEL, KEYNOTE-667 STUDY. (23rd June 2022) Authors: Vinti, L.; Daw, S.; Sabado Alvarez, C.; Fagioli, F.; Beishuizen, A.; Michel, G.; Moleti, M. L.; Cepelova, M.; Thorwarth, A.; Rigaud, C.; Plaza Lopez de Sabando, D.; Landman Parker, J.; Zhu, Y.; Pillai, P.; Nahar, A.; Mauz-Koerholz, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗